Impeto Medical

Executive Summary

Impeto Medical is a French medical device company specializing in non-invasive diagnostics for autonomic and small fiber neuropathies. Its flagship product, SUDOSCAN, provides rapid, painless assessment of sweat gland function, enabling early detection and monitoring of conditions such as diabetic neuropathy, Parkinson's disease, and chemotherapy-induced peripheral neuropathy. The technology is supported by over 100 peer-reviewed publications and is used in more than 1,000 clinical sites worldwide, including prominent hospitals and research institutions. With a strong presence in Europe and Asia, Impeto is now pursuing FDA clearance for expanded indications in the US, targeting a large addressable market of over 100 million patients with neuropathy risk. The company's competitive advantages include its non-invasive nature (no needles, no radiation), ease of use at point-of-care, and ability to detect dysfunction before symptoms appear. Financially, Impeto has raised undisclosed funding, likely from European health-tech investors, and generates recurring revenue from consumables. The company faces competition from nerve conduction studies, skin biopsies, and emerging digital biomarkers, but maintains a differentiated position through its unique technology and clinical validation. Given the growing prevalence of diabetes and aging populations, Impeto is well-positioned for growth, though commercialization in the US remains a key challenge. Overall, the company represents a specialized but promising opportunity in the medtech diagnostic space.

Upcoming Catalysts (preview)

• Q4 2026FDA Clearance for Diabetic Neuropathy Indication70% success
• Q2 2026Publication of Large-Scale Clinical Study in Neurology80% success
• H1 2027Strategic Partnership with Major Diabetes Device Company50% success